CALCIUM CHANNEL BLOCKERS IN COMBINATION: WHAT WE ARE LEARNING FROM CLINICAL TRIALS
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Calcium channel blockers (CCBs) are widely used antihypertensive agents due to their efficacy in lowering blood pressure (BP), regardless of the age or ethnic background of the patient. Calcium channel blockers clearly prevent cardiovascular (CV) events and reduce mortality, as demonstrated recently in the CAMELOT (Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis) study. In this doubleblind, randomized, multicenter trial, amlodipine therapy decreased BP by an average of 5/3 mm Hg, and, in comparison with placebo, reduced the risk of CV events (31% relative reduction, 6.5% absolute reduction) in normotensive (average baseline BP 129/78 mm Hg) patients with angiographically documented coronary artery disease. In comparison, enalapril therapy decreased BP by an average of 5/2 mm Hg, but was associated with a nonsignificant reduction in CV events (15.3% relative reduction, 2.9% absolute reduction). It is notable that a CAMELOT intravascular ultrasound substudy showed that amlodipine therapy was associated with evidence of slowing of atherosclerosis progression.
Major studies have shown that most hypertensive patients need 2 or more drugs to reach goal BP. For example, in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), the largest of the hypertension trials (Nϭ33, 357), 63% of patients required greater than or equal to 2 drugs to achieve BP control. Therefore, the question of what class of antihypertensive agent works best to reduce BP and to prevent target-organ damage when used in combination with a CCB is important. Recent clinical trials offer important signposts. A report from the Women's Health Initiative Observational Study indicated that therapy with a combination of a CCB plus a diuretic is associated with a higher risk of CV mortality compared with beta-blocker/diuretic or angiotensin-converting enzyme inhibitor/diuretic combination therapy. However, as a purely observational study, this study can provide no evidence of a causal connection. Therefore, the results of ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) are eagerly awaited following the early termination of the trial in 2004 due to significant CV benefits seen in the amlodipine/perindopril arm of the study versus the atenolol/ bendroflumethiazide arm. The ASCOT trial was a prospective, randomized trial of hypertensive patients (Nϭ19,342) with greater than or equal to 3 additional CV risk factors. Results from studies such as ASCOT will be important benchmarks in determining optimal combination antihypertensive therapy, including initial therapy, particularly in high-risk and difficult-to-treat patient populations.
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EXTENDING THE BENEFITS OF COMBINATION ANTIHYPERTENSIVE THERAPY TO MORBIDITY AND MORTALITY REDUCTION
Bertram Pitt. University of Michigan Medical School, Ann Arbor, MI.
The ultimate reason for lowering blood pressure (BP) is to reduce the morbidity and mortality associated with hypertension. In clinical trials, antihypertensive therapy has been associated with reductions in stroke incidence averaging 35%-40%; reductions in myocardial infarction of 20%-25%; and reductions in heart failure Ͼ50%. Combination therapy in hypertension, using low doses of 2 or more agents, increase BP-lowering efficacy and improves tolerability, compared with monotherapy. The possibility exists that specific combination therapies could improve cardiovascular (CV) outcomes, not only through controlling BP but also through mechanism-specific CV and renal-protective benefits beyond BP reduction. While the use of combination antihypertensive therapy is needed to achieve BP in the majority of patients, sparse clinical trial data are available for determination of the optimal selection of agents for combination therapy.
Recent large, clinical hypertension trials such as ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) and ANBP-2 (the second Australian National Blood Pressure Study) have reached different conclusions regarding the optimal agent to use when initiating antihypertensive therapy. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) has followed the findings of ALLHAT in recommending the use of thiazide diuretics for initiating therapy in patients with uncomplicated hypertension. However, few patients with hypertension are actually uncomplicated. Perhaps the most important question to be answered is not which antihypertensive class should be utilized for initiation of therapy, but which combination of agents will produce the best clinical outcomes in hypertensive patients?
An exciting possibility is that specific drug combinations may confer target-organ protection in addition to and independent of their BP-268A AJH-May 2005-VOL. 18, NO. 5 , PART 2 FACULTY ABSTRACTS lowering effects. However, the merits of various combinations of antihypertensive agents have not previously been studied in prospective, randomized, controlled clinical trials. A new clinical trial, ACCOM-PLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension), is the first large clinical trial to directly compare CV mortality and morbidity rates for 2 fixeddose combination therapies. The ACCOMPLISH trial will evaluate whether an angiotensin-converting enzyme (ACE) inhibitor/calcium channel blocker combination or an ACE inhibitor/diuretic combination provides greater benefits in reducing morbidity and mortality from CV events in a high-risk hypertensive population. The trial will randomize subjects to either amlodipine besylate/benazepril HCl (Lotrel) or benazepril HCl/diuretic, and is currently recruiting patients from the United States and Northern European countries. There is substantial study evidence supporting the use of ACE inhibitors in hypertensive patients with diabetes, renal insufficiency and/or proteinuria. Thus, the use of the ACE inhibitor benazepril in both treatment groups allows for the inclusion of these important high-risk patient subgroups in the ACCOMPLISH trial. Results from ACCOMPLISH should provide much-needed guidance for selecting optimal combination therapy for high-risk hypertensive patients.
